Vir Biotechnology Secures $150 Million in $8.50 Share Public Offering
Vir Biotechnology has priced an underwritten public offering of 17,647,058 common shares at $8.50 apiece, expected to raise $150 million before expenses. The offering includes a 30-day underwriter option for up to 2,647,058 additional shares and is slated to close on February 27, 2026.
1. Offering Pricing
Vir Biotechnology has agreed to sell 17,647,058 shares of its common stock at a public offering price of $8.50 per share, generating gross proceeds of approximately $150 million before underwriting discounts, commissions and estimated offering expenses.
2. Underwriter Option and Closing
The underwriters have a 30-day option to purchase up to an additional 2,647,058 shares at the same public offering price less discounts and commissions. The transaction is expected to close on February 27, 2026, subject to customary closing conditions.
3. Underwriting and Registration
Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI and Barclays are acting as book-running managers. The shares are being offered under an effective shelf registration statement on Form S-3 filed with the SEC on November 3, 2023.